Inhibition of SLC25A1 could inhibit the growth of different tumor types26,27 and revert steatosis, glucose intolerance, and inflammation in preclinical models of nonalcoholic fatty liver disease/inflammatory steatohepatitis28. Here, SLC25A1 is linked to metabolic dysfunction-associated steatotic liver disease.